Tate & Lyle Regulatory News. Live TATE RNS. Regulatory News Articles for Tate & Lyle Plc Ord 29 1/6p
Tate & Lyle Regulatory News. Live TATE RNS. Regulatory News Articles for Tate & Lyle Plc Ord 29 1/6p
www.lse.co.ukHere are the latest publicly available updates on Tate & Lyle.
-
Trading performance and recent developments: Tate & Lyle reported solid quarterly operating performance with volume and EBITDA growth, and strong cash generation. The CP Kelco acquisition completed in November, and the group emphasized progress on integrating CP Kelco and delivering run-rate cost synergies of about $50 million by the end of fiscal 2027 [source: Trading Statement and Company Announcements from February 2025] [source: TATE regulatory news release 13 Feb 2025]. The company also noted that demand remained broadly stable but with pricing pressure and geopolitical uncertainty weighing on outcomes for the 2025 calendar year [source: Trading Statement 13 Feb 2025].
-
Near-term outlook: For the 2025 calendar year, Tate & Lyle anticipated volume and revenue growth driven by renewed contracts and the expanded portfolio from CP Kelco, while maintaining a cautious stance due to macro uncertainty. They reiterated an unchanged outlook for the full year as of the late-2025/trading-period communications, with focus on top-line growth initiatives and integration progress [source: Trading Statement 13 Feb 2025; Company updates through 2025 calendar year communications].
-
Market reaction and context: Coverage in financial press noted an upgraded sentiment around Tate & Lyle in mid-2025 as investors evaluated CP Kelco-related synergies and the company’s repositioning strategy. The stock news flow included coverage of market expectations and equity research names, reflecting a cautiously positive stance on growth potential tied to CP Kelco’s contribution and improved margin trajectory [sources: 2025 market news summaries and broker commentary].
If you’d like, I can pull the most recent press releases or regulatory announcements from Tate & Lyle’s website and summarize the exact figures (volumes, EBITDA, synergies, and full-year outlook) with dates. I can also build a quick timeline or pull any available investor presentations for deeper context.